Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016

Executive Summary

A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.


Related Content

Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia
Keeping Track: Oncology Approvals And Responses To Complete Response Letters
Neurocrine Gets First Drug For Tardive Dyskinesia To FDA
Teva CRL Response For Huntington’s Drug Targeted For September
Pressure off Teva's CNS hopes as tardive dyskinesia drug succeeds
Teva Makes A Specialty M&A Play In Deal To Buy Auspex


Related Companies